PCI Pharma Services
Overall Rank: 6
Category Rank: 4
- Top HealthTech Company of 2023
PCI Pharma Services is a global CDMO that specializes in drug development, manufacturing, and packaging solutions, facilitating product speed to market and commercial success for clients. Headquartered in Philadelphia, PCI employs leading technology to address drug development needs throughout the product life cycle, from manufacturing to clinical trial supply chains and commercialization.
As part of their digital transformation strategy, PCI developed and launched pci | bridgeTM, an innovative digital platform providing customers immediate visibility into their clinical and commercial supply chain. Since then, the platform has evolved tremendously, integrating new digital technologies and enhancing the user experience for their customers.
With over five decades in the healthcare services sector, PCI has a track record of more than 90 successful product launches each year. They operate across 30 sites in seven countries, employing over 5,200 individuals.
Recent developments include the establishment of a new Center of Excellence Facility in the Midwest, expansion of sterile fill-finish capabilities in Melbourne and San Diego, and plans for a new $50 million facility in Rockford, which will create 250 jobs and strengthen PCI’s pharmaceutical solutions.
Drug Development & Manufacturing
PCI are experts and innovators offering full service formulation development including in-house analytical development services for both sterile and non-sterile dosage forms. Our scalable development and manufacturing capabilities for tablets, capsules, gels, ointments, liquids, sterile dosage forms and lyophilized drug products aid delivery of life-changing therapies to patients from early phase clinical trials through to commercialization.
Clinical Trial Services
PCI provides a global service with localized focus, delivering over 200 protocols a year in over 100 countries, utilizing best-in-class technologies combined with our experienced and dedicated teams. Providing a seamless service, PCI supports the global supply of investigational medicines with pharmaceutical development, clinical drug product manufacturing, packaging, labeling, storage and distribution and full returns service.
With true customer focus and flexibility at the core of our commercial packaging services, we are able to support the unique requirements of each product type and global market supplied. Utilizing state-of-the-art packaging technologies, we provide advanced primary, secondary and tertiary packaging solutions for a diverse portfolio of conventional dosage forms including oral solids, powders, liquids, creams and gels, as well as specialist injectable and parenteral delivery forms including vials, cartridges, prefilled syringes and auto-injectors.
pci | bridgeTM
PCI’s commitment and investment in digital transformation is an exciting journey and uses industry-leading technology to differentiate what we do. pci | bridgeTM has been developed to complement our customer service and project management capabilities by creating efficient and uncomplicated ways of working together.
pci | bridgeTM is an industry-leading digital customer platform designed to provide clients with real-time insights into their portfolio of work at our sites around the globe, unlocking productivity with access to real-time supply chain information and digital workflows.
Our innovative platform provides clients with real-time visibility of their supply chain using cross-functional workflows and data-driven insights providing an enhanced customer experience through digital transformation.
Best-in-class Capabilities and Quality
Customers recognize PCI for superior packaging capabilities among competitors and our ability to tailor solutions around unique packaging requirements. Our expertise and delivery is “second-to-none” when it comes to Package Design and Development as well as Project Management support for new products coming to market.
Quality is non-negotiable for our customers which has been recognized as a clear strength at every PCI location among our global network along with GMP compliance. With over 130 successful regulatory inspections covering all major, global regulatory agencies over the last five years, our demonstrable track record in quality is central to our service offering, to ensure the safety of patients world-wide.
pci | bridgeTM
Clients consider pci | bridgeTM a valuable resource that their teams utilize on a daily basis to track shipments, monitor inventory and more. As an innovative and best-in-class system, it is a true differentiator in terms of supply chain visibility and planning within the CDMO market place.
Supply chain data is critical and at the pace pharmaceutical developments can change, it’s vital for clients to have access to real-time data. No matter the complexity, pci | bridgeTM provides data at whatever level of detail is required and at each step of the supply chain meaning clients are able to make informed business decisions, keep projects on track and most importantly, ensure the right therapies are delivered to the right patients at the right time.
PCI Pharma Services
- Founded in 1967.
- 5,200+ employees
- 90+ Product launches supported every year
- 50+ years of experience in Commercial Packaging
- 35+ year of high potent development & manufacturing expertise
- 25+ years of experience in lyophilization & sterile fill-finish services
- 25+ years of experience in biotech
pci | bridgeTM
- 3+ years of platform evolution
- 24 releases of features and enhancements in the last 12 months
- +40% increase in process-supporting platform utilization in last 12 months
- 200+ client user enablement trainings conducted in last 12 months
- Multi-Million dollar investment in platform development in last fiscal year
- 4,600+ clinical protocols and commercial products enhanced by pci | bridgeTM
PCI Pharma Services' Video
- Salim Haffar, CEO
- Tom DeWeerdt, Chief Financial Officer
- Angi Calkins, Chief Human Resources Officer
- Jeannie Metzinger, Chief Compliance and Quality Officer
- Brad Payne, Chief Operating Officer
- John Ross, SVP Development and Manufacturing
- Tim Roberts, Chief Commercial Officer
- John Cullivan, Chief Corporate Development Officer
- Wayne Hull, Chief Digital & Technology Officer
- Ed Malatesta, SVP, Global Sales, Commercial Packaging
- Brian Keesee, SVP Clinical Trial Services
- Gil Valadez, SVP Commercial Packaging Technology
At PCI diversity, equity, and inclusion are core to our company’s culture and essential to our purpose to serve as the bridge between life changing therapies and patients. We are committed to cultivating an inclusive workplace by holding ourselves accountable to the highest standards of fairness, respect, and equal opportunity at every level.
We envision a PCI community where everyone feels they belong and can flourish, and we strive to make this vision a reality by continuously and intentionally assessing our People practices, policies and programs, marketing approach, and workplace culture.
PCI is committed to providing market competitive and comprehensive compensation and benefits plans that reflect the local marketplaces in which PCI has a presence and employees. Our Total Rewards structure is grounded in fairness, transparency and equal opportunity and are designed to meet the diverse needs of our employees and their families.
Kohlberg & Company, LLC and Mubadala Investment Company and Partners Group
News and Press Releases
- March 2023: PCI Pharma Services is pleased to announce plans for a new 200,000-square-foot facility in Rockford, Illinois, to enhance the organization’s capacity in injectable drug-device combination product assembly of biologics and small molecules (Read)
- July 2022: PCI Pharma Services Selects Thoughtworks for Digital Platform Transformation with Agile Approach (Read)
- April 2022: PCI receives score of 54 and Bronze medal from EcoVadis, the leading platform for environmental, social and ethical performance ratings. This is a 70% increase from our previous assessment result and effectively puts PCI among the top 32% of all companies assessed by EcoVadis (Read)
- December 2021: PCI acquired Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO) headquartered in Bedford, New Hampshire (Read)
- September 2020 – PCI launched pci | bridgeTM, an innovative digital platform provides customers immediate visibility into their clinical and commercial supply chain (Read)
At PCI, the company has served as the bridge connecting life-changing therapies to patients for over half a century. This profound responsibility is met with an unwavering passion and a sense of humility. Guided by values such as accountability, flexibility, and excellence, the team at PCI is dedicated to aiding customers in the production of critical medications for both clinical trials and the broader public.
The Environmental Social Governance (ESG) strategy embraced by PCI embodies these core values and reflects the company’s commitment to customers, communities, and the planet. It recognizes the pivotal role PCI plays in the pharmaceutical supply chain, delivering products that enhance and prolong lives. This commitment to sustainability is driven by the profound societal dependence on their business.
PCI has fully integrated ESG considerations into its daily operations, empowering employees at every site to translate their ideas into tangible actions that positively impact the world. The ESG program at PCI is structured around nine key impact categories, serving as the pillars of change. The company is resolute in its dedication to these areas, aiming to drive global progress as a unified, global Contract Development and Manufacturing Organization (CDMO). KPIs, targets, and sustainability frameworks have been carefully chosen for each category, aligning with the priorities of stakeholders. This strategic approach ensures that PCI remains focused, inclusive, authentic, ambitious, and results-oriented in its pursuit of ESG goals.
PCI’s commitment to ESG is evident in its current initiatives. These include extensive support for STEM projects in local communities, partnerships with suppliers and collaborators to promote sustainable packaging solutions, and a concerted effort to reduce waste sent to landfills. The company is also firmly committed to addressing climate change and reducing its carbon footprint, actively contributing to the global effort to halve emissions by 2030.
PCI’s commitment extends to measuring progress within the local and global communities where it operates and serves. The company recognizes that its global purpose is rooted in local actions, and the positive impact created in smaller communities ripples outward to shape a more significant global influence.
PCI approaches its ESG journey with utmost seriousness, holding itself accountable for tangible results. Recognizing that its approach, processes, and targets may evolve over time, the company commits to transparency and continual improvement. Lessons learned along the way will be openly shared and leveraged to refine and enhance its ESG initiatives.